You are here: Industry Insights > NICE

News List

NICE turns down kidney cancer drugs pharmatimes
August 15, 2017
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
NICE approves three quarters of the Cancer Drugs Fund europeanpharmaceuticalreview
August 15, 2017
NICE has recommended sorafenib to be routinely available for patients on the NHS making it one of the 24 drugs appraised from the CDF…
Bayer's Nexavar approved for primary liver cancer by NICE pharmatimes
August 11, 2017
Nexavar, funded through the Cancer Drugs Fund, has been the only option of advanced liver cancer patients in England.
Bayer's liver cancer drug availability spreads to UK with NICE approval pharmafile
August 11, 2017
NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma (HCC) ...
NICE recommends Merck’s erbitux to treat R/M SCCHN in oral cavity pharmaceutical-technology
August 11, 2017
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Merck’s erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat recurrent and / or metastatic (R/M) squamous cell carcinoma of the he
Merck scores expanded NICE recommendation in head, neck and oral cancer pharmafile
August 09, 2017
Merck has announced its approval of NICE’s decision to expand its recommendation of Erbitux (cetuximab) to include its use as a first-line treatment for recurrent or...
NICE backs new treatment option for psoriasis pharmatimes
August 08, 2017
The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment pharmafile
August 07, 2017
Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination with gemcitabine...
Roche’s Tecentriq hits trouble with NICE in bladder cancer pharmaphorum
August 04, 2017
NICE has said Roche’s cancer immunotherapy Tecentriq (atezolizumab) should not receive regular NHS funding as a treatment for bladder cancer in first draft guidance...
NICE invites Roche to submit Tecentriq for CDF pharmatimes
August 04, 2017
Roche’s Tecentriq has been rejected by NICE as a ‘routine’ treatment for advanced bladder cancer, but the drugmaker has been asked to submit a proposal for ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page